Are patients with COPD more adherent to single-inhaler compared with multiple-inhaler triple therapy in a real-world UK primary care treated population?
K. Rothnie (London, United Kingdom), A. Czira (London, United Kingdom), C. Compton (London, United Kingdom), V. Banks (Bollington, United Kingdom), R. Wood (Bollington, United Kingdom), T. Tritton (Bollington, United Kingdom), J. Thomas (Bollington, United Kingdom), O. Massey (Bollington, United Kingdom), S. Blackburn (Bollington, United Kingdom), R. Wild (Bollington, United Kingdom), A. Ismaila (Upper Providence, United States of America)
Source: Virtual Congress 2021 – COPD pharmacology: from basic science to real-world data
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Rothnie (London, United Kingdom), A. Czira (London, United Kingdom), C. Compton (London, United Kingdom), V. Banks (Bollington, United Kingdom), R. Wood (Bollington, United Kingdom), T. Tritton (Bollington, United Kingdom), J. Thomas (Bollington, United Kingdom), O. Massey (Bollington, United Kingdom), S. Blackburn (Bollington, United Kingdom), R. Wild (Bollington, United Kingdom), A. Ismaila (Upper Providence, United States of America). Are patients with COPD more adherent to single-inhaler compared with multiple-inhaler triple therapy in a real-world UK primary care treated population?. 2947
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: